| Literature DB >> 23880854 |
Aaron Robertson1, James Allen, Robin Laney, Alison Curnow.
Abstract
Radon-222 is a naturally occurring radioactive gas that is responsible for approximately half of the human annual background radiation exposure globally. Chronic exposure to radon and its decay products is estimated to be the second leading cause of lung cancer behind smoking, and links to other forms of neoplasms have been postulated. Ionizing radiation emitted during the radioactive decay of radon and its progeny can induce a variety of cytogenetic effects that can be biologically damaging and result in an increased risk of carcinogenesis. Suggested effects produced as a result of alpha particle exposure from radon include mutations, chromosome aberrations, generation of reactive oxygen species, modification of the cell cycle, up or down regulation of cytokines and the increased production of proteins associated with cell-cycle regulation and carcinogenesis. A number of potential biomarkers of exposure, including translocations at codon 249 of TP53 in addition to HPRT mutations, have been suggested although, in conclusion, the evidence for such hotspots is insufficient. There is also substantial evidence of bystander effects, which may provide complications when calculating risk estimates as a result of exposure, particularly at low doses where cellular responses often appear to deviate from the linear, no-threshold hypothesis. At low doses, effects may also be dependent on cellular conditions as opposed to dose. The cellular and molecular carcinogenic effects of radon exposure have been observed to be both numerous and complex and the elevated chronic exposure of man may therefore pose a significant public health risk that may extend beyond the association with lung carcinogenesis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23880854 PMCID: PMC3742230 DOI: 10.3390/ijms140714024
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The decay series of uranium-238 indicating its decay products, their half-lives and the electron configuration of radon-222 complete with each respective atomic number.
Energy emissions (MeV) of the radon-222 decay series.
| Isotope | Emission energy (MeV) | Decay type |
|---|---|---|
| Radon-222 | 5.49 | α |
|
| ||
| Polonium-218 | 6.00 | α |
|
| ||
| Lead-214 | 0.67, 0.73 | β |
| 0.35, 0.30, 0.24 | γ | |
|
| ||
| Bismuth-214 | 1.54, 1.51, 3.27 | β |
| 0.61, 1.76, 1.12 | γ | |
|
| ||
| Polonium-214 | 7.69 | α |
|
| ||
| Lead-210 | 0.06, 0.02 | β |
| 0.05 | γ | |
|
| ||
| Bismuth-210 | 1.16 | β |
| 0.27, 0.30 | γ | |
|
| ||
| Polonium-210 | 5.30 | α |
|
| ||
| Lead-206 | Stable | |
Estimated lifetime risk of lung cancer death by radon level for never smokers, current smokers and the general population assuming lifetime exposure (adapted from United States Environmental Protection Agency [55]).
| Radon level Bq/m3 | Lifetime risk of lung cancer death from radon exposure in homes (%) | ||
|---|---|---|---|
|
| |||
| Never smokers | Current smokers | General population | |
| 740 | 3.6 | 26.3 | 10.5 |
| 370 | 1.8 | 15 | 5.6 |
| 296 | 1.5 | 12 | 4.5 |
| 148 | 0.7 | 6.2 | 2.3 |
| 74 | 0.4 | 3.2 | 1.2 |
| 46.25 | 0.2 | 2 | 0.7 |
| 14.8 | 0.1 | 0.6 | 0.2 |
Key human TP53 analyses of exposure to radon or its surrogates.
| Exposure | Cancer/cell type | G to T hotspot transversion | Number of observed mutations/number of cancers studied | Exon(s) sequenced | Reference |
|---|---|---|---|---|---|
| - | NS | Not evident | 7/19 | 5–9 | [ |
| 1382 WLM | 11 LCC; 41 SCC | (16/29) | 29/52 | 5–9 | [ |
| - | 23 AC | Not evident | 0/23 | 5–9 | [ |
| 4 Gy (~1460 WLM) | NHBE cells | Not evident | - | 7 | [ |
| ~1160 WLM (estimated mean) | 19 AC; 19 SmCC; 9 SCC; 2 Mixed; 1 ASC | Not evident | 5/50 | 7 | [ |
| <50 or >140 Bq·m−3 | 73 SmCC; 59 SCC; 86 AC; 25 Other | Not evident | 58/243 | 5–8 | [ |
| ~1100 WLM | 19 AC; 19 SmCC; 9 SCC; 3 Mixed | Not evident | 5/50 | 7 | [ |
| - | 16 SCC; 11 AC; 1 SmCC; 1 LCC | Rare (1/29) | 12/29 | 5–7 | [ |
| - | 29 SCC | Rare (2/29) | Not reported/29 | 7 | [ |
| 11.1–51.8 Bq·m−3 | NS | Not evident | 0/4 (Only 4/16 could be analysed) | 4–8 | [ |
Exposures are based on presented values;
Abbreviations: NS (not specified); LCC (large cell carcinoma); SCC (squamous cell carcinoma); AC (adenocarcinoma); NHBE (normal human bronchial epithelial); ASC (adenosquamous carcinoma).
Key cytogenetic analyses of exposure to radon or its surrogates in vitro with identified doses.
| Exposure | Cell type | Dose range | Dose rate | Energy (MeV) | Investigated abnormality | Reference |
|---|---|---|---|---|---|---|
| 212Bi | CHO-K1; xrs-5 | 1–5 Gy | 0.125–0.5 Gy/h | CellSurvival; CAs; HPRT mutations | [ | |
| 222Rn | Blood lymphocyte | 2–18 cGy | 15 cGy/h | Chromatid deletions | [ | |
| 238Pu | Multipotential murine marrow | 0.25–1 Gy | - | 3.3 | CAs | [ |
| 238Pu | Multipotential human marrow | 0.25–1 Gy | - | CAs | [ | |
| 238Pu | 10T1/2; 3T3 | 2.5–5 cGy | - | 5.3 | CAs; SCEs | [ |
| 238Pu | CHO | 0.16–4.9 mGy | 0.147 Gy/min | 3.7 | SCEs | [ |
| 238Pu | HFL1 | 0.4–12.9 cGy | 3.65 cGy/s | 3.5 | SCEs | [ |
| 238Pu | HFL1 | 1.8–12.9 cGy | 3.65 cGy/s | 3.5 | SCE | [ |
| 238Pu | HFL1 | 0.4–19 cGy | 3.65 cGy/s | 3.5 | ROS generation | [ |
| 238Pu | HFL1 | 1–19 cGy | 3.65 cGy/s | 3.5 | ROS, TP53, CDC2, CDKN1A and TGF-β1 generation; cell proliferation | [ |
| 238Pu | AG1521; AG1522; GM5758; GM6419; GM8333 | 0.3–75 cGy | 9.9 cGy/min | 3.65 | TP53, CDC2, CDKN1A, RAD51 and CCNB1 generation | [ |
| 214Po | Blood lymphocyte | 0.03–41.4 mGy | - | 7.68 | CA | [ |
| 4He | HBPE | 0.6 Gy | - | 4.0 | Colony formation; malignant transformation; TP53 mutations; CA; invasion ability | [ |
| 222Rn | Blood lymphocyte | 0–127 mGy | - | 5.5 | CA; CBMN | [ |
| 222Rn | Blood lymphocyte | 0.9–5.2 mGy | - | 5.5 | CA | [ |
Abbreviations: CA (Chromosome/chromatid aberrations); SCE (Sister chromatid exchanges); ROS (Reactive oxygen species); CBMN (Cytokinesis blocked micronuclei).
Figure 2Examples of (a) intra-chromosomal aberrations (including pericentric inversions and the formation of centric rings and acentric fragments); (b) Inter-chromosomal aberrations (including translocations and the formation of dicentric and acentric fragments); and (c) Sister chromatid exchange (whereby genetic material is exchanged between two sister chromatids).
Figure 3Graphical representation of some of the suggested hypotheses of dose-response functions at low doses, including hormetic, threshold, linear no threshold and supralinear (u-shaped) responses.